The Advisory Committee on Immunization Practices (ACIP) recommends the tick-borne encephalitis (TBE) vaccine for individuals in the US traveling to TBE endemic areas with extensive outdoor exposure to infected ticks, as well as for laboratory workers. The vaccine was approved by the FDA in August 2021 for individuals aged 1 year and older. Studies conducted in Europe showed a vaccine effectiveness of 91% to 99% following receipt of 3 or more doses. Data also showed high seropositivity rates in adults and children who received the 3-dose primary series, as well as an increase in immune response to a booster dose 3 years after. Safety analysis showed that the most common reactions were pain and tenderness at the injection site, fatigue, headache, and fever. However, data from special populations, such as pregnant individuals and older adults, are limited. Further research is needed to assess the clinical spectrum of TBE virus infection during pregnancy.
Source link
Tick-Borne Encephalitis Vaccine Recommended for US Travelers
